Suggested remit: To appraise the clinical and cost effectiveness of Beremagene geperpavec within its marketing authorisation for treating skin wounds assocatied with dystrophic epidermolysis bullosa.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Further information:
- The topic routing was re-considered by the Topic Selection Oversight Panel (TSOP) in September 2023. The panel concluded that the topic should remain routed to the Technology Appraisal (TA) work programme. Please see project documents for further details. The timelines for the evaluation are to be confirmed.
- Process:
- STA Standard
- ID number:
- 3959
Provisional Schedule
- Committee meeting: 1:
- 03 September 2025
- Expected publication:
- 29 January 2026
Project Team
- Project lead
- Jeremy Powell
Email enquiries
If you have any queries please email [email protected]
- External Assessment Group:
- School of Health and Related Research (ScHARR), University of Sheffield
Stakeholders
- Companies sponsors
- Krystal Biotech Inc (beremagene geperpavec)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Anthony Nolan
- Beacon
- Changing Faces
- Cure EB
- DEBRA UK
- Gene People
- Genetic Alliance UK
- Let’s Face It
- South Asian Health Foundation
- Specialised Healthcare Alliance
- Professional groups
- Counsellors
- Association of Paediatric Emergency Medicines
- British Association of Dermatologists
- British Dermatological Nursing Group
- British Geriatrics Society
- British Society for Cutaneous Allergy
- British Society for Gene and Cell Therapy
- British Society for Genetic Medicine
- British Society for Paediatric and Adolescent Dermatology
- British Trauma Society
- National Diagnostic Epidermolysis Bullosa Laboratory
- Neonatal and Paediatric Pharmacists Group
- Primary Care Dermatology Society
- Royal College of Emergency Medicine
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Paediatrics & Child Health
- Royal College of Pathologists
- Royal College of Physicians
- Royal Pharmaceutical Society
- Royal Society of Medicine
- Society of Tissue Viability
- St John's Institute of Dermatology
- Surgical Dressing Manufacturers Association
- UK Clinical Pharmacy Association
- Associated public health groups
- Public Health Wales
- UK Health Security Agency
- Comparator companies
- Chiesi (Birch bark extract)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- Allied Health Professionals Federation
- Board of Community Health Councils in Wales
- British National Formulary
- Care Quality Commission
- Cell and Gene Therapy Catapult
- Department of Health- Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- National Association of Primary Care
- National Pharmacy Association
- NHS Confederation
- Scottish Medicines Consortium
- Welsh Government
- Welsh Health Specialised Services Committee
- Relevant research groups
- University Hospitals Birmingham, Adult Epidermolysis Bullosa Service
- Birmingham Women’s and Children’s Hospital, Epidermolysis Bullosa Service
- British Skin Foundation
- Centre of Evidence-based Dermatology, University of Nottingham
- Cochrane Skin Group
- Dermatrust
- Genomics England
- Great Ormond Street Children’s Hospital, London, Dermatology
- Guy’s and St Thomas’ Hospital, London, Dermatology
- Health Services Research Unit, Department of Public Health, University of Oxford
- Skin Inflammation Genetics Group, King’s College London
- MRC Clinical Trials Unit
- National Institute for Health Research
- Wounds UK
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 10 February 2025 | Invitation to participate |
| 02 December 2024 - 16 December 2024 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 02 December 2024 | In progress. We consulted on the draft scope for this appraisal in 2022. The appraisal was paused but is now restarting. To ensure that the scope is up to date we are now holding a short second consultation. |
| 15 January 2024 | The topic routing was re-considered by the Topic Selection Oversight Panel (TSOP) in September 2023. The panel concluded that the topic should remain routed to the Technology Appraisal (TA) work programme. Please see project documents for further details. The timelines for the evaluation are to be confirmed. |
| 11 January 2024 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
| 11 January 2024 | Topic selection |
| 28 July 2023 | Following a routing challenge raised by the company, regarding the Topic Selection Oversight Panel (TSOP) decision to route Beremagene Geperpavec as a Technology Appraisal, the start of this evaluation is delayed. The timelines for the evaluation will be confirmed once TSOP have reviewed the challenge. |
| 14 June 2023 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
| 14 June 2023 | Topic selection |
| 14 June 2023 | Topic selection. Routing update |
| 19 January 2023 (14:00) | Scoping workshop |
| 09 November 2022 - 07 December 2022 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 20 May 2022 | In progress. Scoping commencing |
For further information on our processes and methods, please see our CHTE processes and methods manual